Effects of glutamate and α2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats

Toxicology and Applied Pharmacology

Volumn 240, Issue 2, 2009, Pages 198-207

  Alam, Mesbah ^a   Danysz, Wojciech ^b   Schmidt, Werner Jürgen ^a   Dekundy, Andrzej ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Complex I inhibition; Dopamine; Glutamate; Neurotoxicity; Parkinson's disease

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; GLUTAMATE RECEPTOR; HOMOVANILLIC ACID; IDAZOXAN; NERAMEXANE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; 6 METHYL 2 (PHENYLETHYNYL)PYRIDINE; 6-METHYL-2-(PHENYLETHYNYL)PYRIDINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; CYCLOPENTANE DERIVATIVE; DOPAMINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; PYRIDINE DERIVATIVE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; HYPOKINESIA; LATENT PERIOD; LOCOMOTION; LONG TERM EXPOSURE; MALE; MUSCLE RIGIDITY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; RAT; SEROTONIN BRAIN LEVEL; SUBSTANTIA NIGRA; ANIMAL; ANIMAL BEHAVIOR; BASAL GANGLION; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; PARKINSONISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME; TOXICITY AND INTOXICATION;

ANIMALIA; PARKINSONIA; RATTUS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BASAL GANGLIA; BEHAVIOR, ANIMAL; CATALEPSY; CYCLOPENTANES; DISEASE MODELS, ANIMAL; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; HYPOKINESIA; IDAZOXAN; MALE; MOTOR ACTIVITY; MUSCLE RIGIDITY; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PARKINSONIAN DISORDERS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; ROTENONE; SEROTONIN; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 70349394996     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.07.010     Document Type: Article

References (58)

1. Agid Y., Javoy-Agid F., and Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden C.D., and Fahn S. (Eds). Movement Disorders 2 (1987), Butterworths, London 166-230
2. Aguirre J.A., Kehr J., Yoshitake T., Liu F.L., Rivera A., Fernandez-Espinola S., Andbjer B., Leo G., Medhurst A.D., Agnati L.F., and Fuxe K. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res. 1033 (2005) 216-220
3. Alam M., and Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136 (2002) 317-324
4. Alam M., and Schmidt W.J. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav. Brain Res. 153 (2004) 439-446
5. Antelman S.M., and Caggiula A.R. Norepinephrine-dopamine interactions and behavior. Science 195 (1977) 646-653
6. Battaglia G., Busceti C.L., Molinaro G., Biagioni F., Storto M., Fornai F., Nicoletti F., and Bruno V. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Neurosci. 24 (2004) 828-835
7. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
8. Bezard E., Brefel C., Tison F., Peyro-Saint-Paul H., Ladure P., Rascol O., and Gross C.E. Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog. Neuropsychopharmacol. Biol. Psychiatry 23 (1999) 1237-1246
9. Bove J., Prou D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2 (2005) 484-494
10. Breysse N., Baunez C., Spooren W., Gasparini F., and Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci. 22 (2002) 5669-5678
11. Breysse N., Amalric M., and Salin P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci. 23 (2003) 8302-8309
12. Cathala L., Guyon A., Eugene D., and Paupardin-Tritsch D. Alpha2-adrenoceptor activation increases a cationic conductance and spontaneous GABAergic synaptic activity in dopaminergic neurones of the rat substantia nigra. Neuroscience 115 (2002) 1059-1065
13. Chopin P., Colpaert F.C., and Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 288 (1999) 798-804
14. Christoffersen C.L., and Meltzer L.T. Evidence for N-methyl-d-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for N-methyl-d-aspartate receptors. Neuroscience 67 (1995) 373-381
15. Coull J.T. Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition. Drug Aging 5 (1994) 116-126
16. Coulom H., and Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J. Neurosci. 24 (2004) 10993-10998
17. Danysz W., and Parsons A.C. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 50 (1998) 597-664
18. Danysz W., Essmann U., Bresink I., and Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav. 48 (1994) 111-118
19. Dekundy A., Pietraszek M., Schaefer D., Cenci M.A., and Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. 69 (2006) 318-326
20. Fredriksson A., Eriksson P., and Archer T. MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN). J. Neural. Transm. 104 (1997) 579-592
21. Grammatopoulos T.N., Ahmadi F., Jones S.M., Fariss M.W., Weyhenmeyer J.A., and Zawada W.M. Angiotensin II protects cultured midbrain dopaminergic neurons against rotenone-induced cell death. Brain Res. 1045 (2005) 64-71
22. Greenamyre J.T., and O'Brien C.F. N-methyl-d-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 48 (1991) 977-981
23. Hallett P.J., and Standaert D.G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 102 (2004) 155-174
24. Heffner T.G., Hartman J.A., and Seiden L.S. A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 13 (1980) 453-456
25. Hesselink M.B., Parsons C.G., Wollenburg C., and Danysz W. Brain distribution of an uncompetitive NMDA receptor antagonist; comparison to its in vitro potency in electrophysiological studies. Naunyn. Schmiedebergs Arch. Pharmacol. 360 (1999) 144-150
26. Hoglinger G.U., Feger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., and Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84 (2003) 491-502
27. Hudson A.L., Robinson E.S., Lalies M.D., Tyacke R.J., Jackson H.C., and Nutt D.J. In vitro and in vivo approaches to the characterization of the alpha2-adrenoceptor. J. Auton. Pharmacol. 19 (1999) 311-320
28. Kaur S., and Starr M.S. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur. J. Pharmacol. 280 (1995) 159-166
29. Klockgether T., Turski L., Honore T., Zhang Z.M., Gash D.M., Kurlan R., and Greenamyre J.T. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30 (1991) 717-723
30. Kosinski C.M., Standaert D.G., Testa C.M., Penney Jr. J.B., and Young A.B. Expression of metabotropic glutamate receptor 1 isoforms in the substantia nigra pars compacta of the rat. Neuroscience 86 (1998) 783-798
31. Lucas D.R., and Newhouse J.P. The toxic effect of sodium l-glutamate on the inner layers of the retina. AMA Arch. Ophthalmol. 58 (1957) 193-201
32. Miranda A.F., Sutton M.A., Beninger R.J., Jhamandas K., and Boegman R.J. Quinolinic acid lesion of the nigrostriatal pathway: effect on turning behaviour and protection by elevation of endogenous kynurenic acid in Rattus norvegicus. Neurosci. Lett. 262 (1999) 81-84
33. Mitchell I.J., Clarke C.E., Boyce S., Robertson R.G., Peggs D., Sambrook M.A., and Crossman A.R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32 (1989) 213-226
34. Moore N.A., Blackman A., Awere S., and Leander J.D. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. Eur. J. Pharmacol. 237 (1993) 1-7
35. O'Leary D.M., Movsesyan V., Vicini S., and Faden A.I. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 131 (2000) 1429-1437
36. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 (2000) S2-S7
37. Olney J.W. Glutamate-induced neuronal necrosis in the infant mouse hypothalamus. An electron microscopic study. J. Neuropathol. Exp. Neurol. 30 (1971) 75-90
38. Ossowska K., Konieczny J., Wolfarth S., Wieronska J., and Pilc A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41 (2001) 413-420
39. Ossowska K., Konieczny J., Wolfarth S., and Pilc A. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 49 (2005) 447-455
40. Parsons C.G., Danysz W., Hesselink M., Hartmann S., Lorenz B., Wollenburg C., and Quack G. Modulation of NMDA receptors by glycine-introduction to some basic aspects and recent developments. Amino Acids 14 (1998) 207-216
41. Plazas P.V., Savino J., Kracun S., Gomez-Casati M.E., Katz E., Parsons C.G., Millar N.S., and Elgoyhen A.B. Inhibition of the α9α10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-d-aspartate receptors. Eur. J. Pharmacol. 566 (2007) 11-19
42. Quik M., and Di Monte D.A. Nicotine administration reduces striatal MPP+ levels in mice. Brain Res. 917 (2001) 219-224
43. Rodriguez M.C., Obeso J.A., and Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 44 (1998) S175-S188
44. Rouse S.T., Marino M.J., Bradley S.R., Awad H., Wittmann M., and Conn P.J. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol. Ther. 88 (2000) 427-435
45. Schmidt W.J., and Kretschmer B.D. Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci. Biobehav. Rev. 21 (1997) 381-392
46. Schmidt W.J., Krahling H., and Ruhland M. Antagonism of AP-5-induced sniffing stereotypy links umespirone to atypical antipsychotics. Life Sci. 48 (1991) 499-505
47. Schmidt W.J., Bubser M., and Hauber W. Behavioural pharmacology of glutamate in the basal ganglia. J. Neural. Transm. Suppl 38 (1992) 65-89
48. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
49. Skuza G., Rogoz Z., Quack G., and Danysz W. Memantine, amantadine, and l-deprenyl potentiate the action of L-dopa in monoamine-depleted rats. J. Neural. Transm. - Gen. Sect. 98 (1994) 57-67
50. Spooren W.P., Gasparini F., Bergmann R., and Kuhn R. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur. J. Pharmacol. 406 (2000) 403-410
51. Srinivasan J., and Schmidt W.J. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur. J. Neurosci. 17 (2003) 2586-2592
52. Srinivasan J., and Schmidt W.J. The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?. Naunyn-Schmied. Arch. Pharmacol. 369 (2004) 629-638
53. Szydlowska K., Kaminska B., Baude A., Parsons C.G., and Danysz W. Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. Eur. J. Pharmacol. 554 (2007) 18-29
54. Tallaksen-Greene S.J., Kaatz K.W., Romano C., and Albin R.L. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Res. 780 (1998) 210-217
55. Turle-Lorenzo N., Breysse N., Baunez C., and Amalric M. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease. Psychopharmacology (Berl) 179 (2005) 117-127
56. Vernon A.C., Palmer S., Datla K.P., Zbarsky V., Croucher M.J., and Dexter D.T. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur. J. Neurosci. 22 (2005) 1799-1806
57. Vernon A.C., Zbarsky V., Datla K.P., Croucher M.J., and Dexter D.T. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J. Neurochem. 103 (2007) 1075-1091
58. Wu Y.N., and Johnson S.W. Rotenone potentiates NMDA currents in substantia nigra dopamine neurons. Neurosci. Lett. 421 (2007) 96-100